Atgen (NKMAX)

2020/06/19 430
  • 品牌国家:韩国
  • 代理区域:中国
  • 代理授权证书:
  • NKMAX拥有适用于对外部环境敏感的蛋白质和需要长期或常温保管的蛋白质的‘蛋白质稳定化融合技术’,以此为基础向全世界多种多样的研究机构供应重组蛋白质及单克隆抗体试药。

    NKMAX SP融合技术 (Super stable-peptide(SP) fusion technology)

    这是NKMAX获得专利的‘蛋白质稳定化融合技术’,是适用于对外部环境敏感的蛋白质和需要长期或常温保管的蛋白质的创新技术。 
    (专利编号:1005067660000 “对环境压力赋予耐性的新多肽及包括它的融合蛋白质”)

    NKMAX 重组蛋白质及单克隆抗体

    基于SP技术,向海外38个国家400多家企业出口重组蛋白质和单克隆抗体。 
    对NKMAX的商业化产品的所有DNA都基于本公司特有的技术进行提取,持有多种多样的DNA数据库。以此为基础利用多样的显性系统和提炼技术,生产高质量的重组蛋白质。并且通过优秀的抗体设计技术和生物信息学、抗体活性检测技术,生产高质量的单克隆抗体。

    NKMAX通过独家的源泉技术和持续的研究开发确保研究用试药领域的世界性专业制造公司的地位,提出世界生物产业研究的创新解决方案。 详细内容请参考研究用试药网站(www.nkmaxbio.com)。

    重组蛋白,抗体和NK Vue等产品订购和价格查询:http://www.rightab.com/brand/8-atgennk-max


    电话:010-83131025


    NKMAX is a biotech company headquartered in South Korea with subsidiaries in Canada and the United States. The company is listed in the Koreans stock Exchange, the Kosdaq. 

    NKMAX was founded in 2002 (as ATGen) on the belief that ‘Health is the greatest wealth’. The company and its employees are committed to both improving quality of life and saving lives—whether by providing novel diagnostic tests, developing new therapies, or providing the research community with quality proteins and antibodies that are crucial for life science advancements. 

    NKMAX manufactures and distributes a large selection of recombinant proteins and monoclonal antibodies to over 200 research institutes in over 20 different countries. 

    The company has also developed and launched an innovative NK Cell function test called NK VUE to help doctors diagnose diseases that are known to affect NK Cell activity. NK VUE bears CE Marking and has been approved by the KFDA and Health Canada. 

    As of 2016, NKMAX has over 100 employees and keeps growing. The company's vision to save as many lives as possible is further reinforced by NKMAX’s current development of immunotherapies.


    ----------
    更多代理品牌资讯,新产品,新领域,新促销,欢迎联系北京华泰昕生物医疗技术有限公司客服了解。
    电话:010-83131025;83130919
    E-mail: info@hypercyte.com